ERBB2 and breast cancer: Moestue ﻿et al. [81] compared metabolomic profiles of basal-like and luminal-like breast cancer xenograft models and samples from patients with estrogen/progesterone receptor positive (ER+/PgR+) or triple negative (ER−/PgR−/HER2−) breast cancer.